Antonio Angrisani, Head Physician at Ente Ospedaliero Cantonale (EOC), shared a post on LinkedIn:
“Truly happy and proud to share that our Policy Review, ‘Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy’ has just been published in The Lancet Oncology!
The paper presents a unique perspective from the ESTRO Focus group on how radiotherapy can enhance the activity of novel anticancer drugs, providing concrete examples of radiotherapy–drug combinations and their diverse potential in terms of efficacy. It ultimately encourages a fundamental shift in the drug development process.
It has been a privilege to contribute to this collaborative effort, and I’m grateful to all co-authors and FG members for their brilliant input, stimulating discussions, and teamwork.
Special thanks to Prof. Dr Dirk De Ruysscher for his leadership and guidance throughout this work.
You can easily find the article available for a short time for free download.
Looking forward to the conversations this work will hopefully spark!”
Title: Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy
Authors: Antonio Angrisani, Youlia Kirova, Azadeh Abravan, Carlotta Becherini, Sergi Benavente, Luis Castelo-Branco, Anthony J Chalmers, Sebastian M Christ, Eric Deutsch, Andrea Riccardo Filippi, Lizza E L Hendriks, Zita Zolcsák, Tim Illidge, Andreas Rimner, Fernanda Herrera, Dirk De Ruysscher.
Read here.
Other articles featuring Dirk De Ruysscher on OncoDaily.